Company logo

AXSM - Axsome Therapeutics, Inc.

NASDAQ -> Healthcare -> Biotechnology
New York, United States
Type: Equity

AXSM price evolution
AXSM
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Current assets
Cash $386.19 $416.56 $437.11 $246.51
Short term investments
Net receivables $94.82 $78.42 $67.41 $44.79
Inventory $15.13 $9.98 $9.25 $7.94
Total current assets $504.26 $511.76 $519.69 $304.45
Long term investments
Property, plant & equipment $7.62 $8.04 $8.15 $0.81
Goodwill & intangible assets $65.33 $66.94 $68.54 $68.4
Total noncurrent assets $83.97 $89.09 $91.95 $84.73
Total investments
Total assets $588.24 $600.86 $611.64 $389.18
Current liabilities
Accounts payable $40.68 $29.1 $42.96 $35.77
Deferred revenue
Short long term debt $1.27 $0.44 $0.35 $0.11
Total current liabilities $138.85 $114.66 $114.97 $100.65
Long term debt $185.1 $185.14 $184.36 $147.62
Total noncurrent liabilities $258.4 $216.69 $217.86 $176.72
Total debt $186.37 $185.57 $184.71 $147.72
Total liabilities $397.26 $331.35 $332.83 $277.37
Shareholders' equity
Retained earnings -$835.57 -$736.92 -$674.72 -$607.55
Other shareholder equity
Total shareholder equity $190.98 $269.51 $278.8 $111.81
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $386.19 $200.84 $86.47 $183.88
Short term investments
Net receivables $94.82 $37.7
Inventory $15.13 $4.32
Total current assets $504.26 $245.64 $86.52 $184.02
Long term investments
Property, plant & equipment $7.62 $1.14 $0.94 $1.79
Goodwill & intangible assets $65.33 $69.97
Total noncurrent assets $83.97 $85.83 $1.27 $2.11
Total investments
Total assets $588.24 $331.48 $87.79 $186.13
Current liabilities
Accounts payable $40.68 $38.61 $13.15 $13.5
Deferred revenue
Short long term debt $1.27 $0.42 $0.62 $1.22
Total current liabilities $138.85 $96.56 $23.07 $23.44
Long term debt $185.1 $94.26 $49.09 $48.9
Total noncurrent liabilities $258.4 $125.36 $49.09 $48.9
Total debt $186.37 $94.68 $49.71 $50.12
Total liabilities $397.26 $221.92 $72.15 $72.34
Shareholders' equity
Retained earnings -$835.57 -$596.33 -$409.2 -$278.8
Other shareholder equity
Total shareholder equity $190.98 $109.56 $15.63 $113.79
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Revenue
Total revenue $71.53 $57.79 $46.7 $94.58
Cost of revenue $7.38 $6.53 $4.6 $7.56
Gross Profit $64.15 $51.26 $42.1 $87.02
Operating activities
Research & development $30.8 $28.77 $20.58 $17.79
Selling, general & administrative $86.81 $83.19 $78.94 $74.19
Total operating expenses $162.43 $113.38 $107.16 $93.39
Operating income -$98.27 -$62.12 -$65.06 -$6.37
Income from continuing operations
EBIT -$98.27 -$62.12 -$65.06 -$6.37
Income tax expense -$0.33 -$0.68 -$0.62 $2.58
Interest expense $0.7 $0.76 $2.73 $2.26
Net income
Net income -$98.65 -$62.2 -$67.17 -$11.22
Income (for common shares) -$98.65 -$62.2 -$67.17 -$11.22
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue $270.6 $50.04
Cost of revenue $26.07 $5.2
Gross Profit $244.53 $44.84
Operating activities
Research & development $97.94 $57.95 $58.06 $70.24
Selling, general & administrative $323.12 $159.25 $66.65 $28.9
Total operating expenses $476.36 $224.64 $124.71 $99.14
Operating income -$231.82 -$179.8 -$124.71 -$99.14
Income from continuing operations
EBIT -$231.82 -$179.8 -$124.71 -$100.39
Income tax expense $0.96 -$0.05
Interest expense $6.45 $7.33 $5.7 $2.57
Net income
Net income -$239.24 -$187.13 -$130.4 -$102.9
Income (for common shares) -$239.24 -$187.13 -$130.4 -$102.9
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Net income -$98.65 -$62.2 -$67.17 -$11.22
Operating activities
Depreciation $2.08 $2.09 $2.15 $1.98
Business acquisitions & disposals
Stock-based compensation $18.91 $14.84 $15.92 $12.94
Total cash flows from operations -$30.36 -$53.55 -$55.35 -$5.82
Investing activities
Capital expenditures -$0.01 -$0.37 -$0.13 -$0.07
Investments
Total cash flows from investing -$0.01 -$0.37 -$0.13 -$0.07
Financing activities
Dividends paid
Sale and purchase of stock $1.15 $38.07 $231.57 $0.39
Net borrowings $0.85 -$0.86 $29.78 $53.78
Total cash flows from financing -$0 $33.37 $246.08 $51.56
Effect of exchange rate
Change in cash and equivalents -$30.37 -$20.55 $190.6 $45.67
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$239.24 -$187.13 -$130.4 -$102.9
Operating activities
Depreciation $8.28 $5.56 $1.16 $0.08
Business acquisitions & disposals -$53
Stock-based compensation $62.62 $37.73 $20.8 $14.76
Total cash flows from operations -$145.08 -$116.51 -$108.23 -$78.46
Investing activities
Capital expenditures -$0.58 -$0.7 -$0.31 -$0.05
Investments
Total cash flows from investing -$0.58 -$53.7 -$0.31 -$0.05
Financing activities
Dividends paid
Sale and purchase of stock $271.17 $243.04 $11.61 $15.18
Net borrowings $83.56 $44.51 -$0.31 $27.24
Total cash flows from financing $331.01 $284.58 $11.13 $42.41
Effect of exchange rate
Change in cash and equivalents $185.35 $114.37 -$97.4 -$36.09
Fundamentals
Market cap $3.78B
Enterprise value $3.58B
Shares outstanding 47.35M
Revenue $270.60M
EBITDA -$223.54M
EBIT -$231.82M
Net Income -$239.24M
Revenue Q/Q 193.50%
Revenue Y/Y 440.80%
P/E ratio -15.79
EV/Sales 13.23
EV/EBITDA -16.01
EV/EBIT -15.44
P/S ratio 13.96
P/B ratio 19.79
Book/Share 4.03
Cash/Share 8.16
EPS -$5.05
ROA -43.70%
ROE -112.44%
Debt/Equity 2.08
Net debt/EBITDA -0.05
Current ratio 3.63
Quick ratio 3.52